

Hong Kong Exchanges and Clearing Limited and the Exchange of Hong Kong Limited take no responsibility for the accuracy or completeness of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from any reliance upon the whole or any part of the contents of this announcement.

The logo for Hepalink, featuring a stylized globe icon with green and blue segments, and the word "Hepalink" in a blue sans-serif font below it.

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9989)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Wednesday, March 30, 2022 for the purposes of, among other matters, approving the annual results of the Group for the year ended December 31, 2021 and its publication, and considering the recommendation of a final dividend, if any.

By Order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
March 18, 2022

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.